Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole

C Mel Wilcox, Toni Martin, Milind Phadnis, Jean Mohnen, Julie Worthington, Basil I Hirschowitz, C Mel Wilcox, Toni Martin, Milind Phadnis, Jean Mohnen, Julie Worthington, Basil I Hirschowitz

Abstract

Background: The relationship between proton pump inhibitor therapy and other acid suppressing medications and the risk of gastrointestinal infections remains controversial.

Methods: Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions. All medications taken were also reviewed at each visit. In addition, available patients were specifically queried during the study period 2006-2007 regarding the development of any gastrointestinal infections, hospitalizations, and prescriptions for antibiotics.

Results: Ninety patients were enrolled in our long-term study and 81 were available for review. The median basal gastric pH for the cohort after stabilization on therapy was 2.9 and ranged from 1.1 - 8.4 with a median pentagastrin stimulated gastric pH of 1.60 (range 1.0 - 8.2). No patient developed a clinically significant gastrointestinal infection during the study. The median patient years of follow-up were 6.25 years.

Conclusion: In a cohort of patients with gastric acid hypersecretion in whom acid secretion status was monitored on lansoprazole, all were free of significant gastrointestinal infections on long-term follow-up.

Trial registration: NCT00204373.

References

    1. Rodríguez LAG, Ruigómez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5:1418–1423. doi: 10.1016/j.cgh.2007.09.010.
    1. Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A, for the Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817–e820. doi: 10.1542/peds.2005-1655.
    1. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile – associated disease. JAMA. 2005;294:2989–2995. doi: 10.1001/jama.294.23.2989.
    1. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea. Aliment Pharmacol Ther. 2006;24:613–619. doi: 10.1111/j.1365-2036.2006.03015.x.
    1. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: A 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3:39–48. doi: 10.1016/S1542-3565(04)00606-8.
    1. Halter F, Keller M. A comparison between intragastric titration and aspiration technique under basal conditions and after food or pentagastrin stimulation. Am J Dig Dis. 1978;23:723–9. doi: 10.1007/BF01072360.
    1. Hirschowitz BI, Groarke J. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls. Dig Dis Sci. 1993;38:1874–84. doi: 10.1007/BF01296112.
    1. Hirschowitz BI, Keeling D, Lewin M, Okabe S, Parsons M, Sewing K, et al. Pharmacological aspects of acid secretion. Dig Dis Sci. 1995;49:3S–23S. doi: 10.1007/BF02214869.
    1. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lantheir L. Emergence of Fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60. doi: 10.1086/496986.
    1. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhea in the elderly. Q J Med. 2000;93:175–181.
    1. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile – associated disease: a population-based study. Clin Infect Dis. 2006;43:1272–6. doi: 10.1086/508453.
    1. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med. 1973;78:271–276.
    1. Cook GC. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:17–23. doi: 10.3109/00365528509093751.
    1. Harder H, Teyssen S, Stephan F, Pfützer R, Kiel G, Fuchs W, Singer MV. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. Scand J Gastroenterol. 1999;34:551–61. doi: 10.1080/003655299750025994.
    1. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol. 2003;98:2616–2620. doi: 10.1111/j.1572-0241.2003.08783.x.
    1. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709–714. doi: 10.1046/j.1365-2036.2000.00775.x.
    1. Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion. 2003;68:184–188. doi: 10.1159/000075697.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit